Yoichi Muramoto

Dr. Yoichi Muramoto

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2023 in Clinical and Translational Radiation Oncology
Verified
Journal Article
Open access
YMYoichi Muramoto
Yoichi Muramoto
NMNaoya Murakami
Naoya Murakami
TKTatsuki Karino
Tatsuki Karino
SSSatoru Sugimoto
Satoru Sugimoto
JTJun Takatsu
Jun Takatsu
NSNaoto Shikama
Naoto Shikama
• MucoUp®, a hyaluronic acid, was used for the first time as a spacer in brachytherapy for uterine cervical cancer. • The study found that MucoUp® can be safely used in gynecologic brachytherapy to create space between CTVHR and OARs, without causing any significant side effects. • MucoUp® insertion enabled the median total CTVHR D90 to exceed 80 Gy while achieving dose constraints of OARs.

1 March 2025 in The Journal of Immunology
Verified
Journal Article
Open access
HLHanbin Lee
Hanbin Lee
CNChigusa Nakahashi-Oda
Chigusa Nakahashi-Oda
WLWenxin Lyu
Wenxin Lyu
MTMamoru Tanaka
Mamoru Tanaka
ARAkiyoshi Rai
Akiyoshi Rai
ASAkira Shibuya
Akira Shibuya
Mast cells (MCs) play a central role in allergic immune responses. MC activation is regulated by several inhibitory immunoreceptors. The CD300 family members CD300a and CD300lf recognize phospholipid ligands and inhibit the FcεRI-mediated activating signal in MCs. While CD300a binds to phosphatidylserine (PS) to inhibit MCs activation, CD300lf function is less clear due to its ability to bind with ceramide and PS. Moreover, it also remains blurring whether CD300a and CD300lf function independently, cooperatively, or by interfering with each other in regulating MC activation. Using imaging and flow cytometric analyses of bone marrow-derived cultured MCs (BMMCs) from wild-type (WT), Cd300a–/–, Cd300lf–/–, and Cd300a–/–Cd300lf–/– mice, we show that CD300lf and CD300a colocalized with PS externalized to the outer leaflet of the plasma membrane with a polar formation upon activation, and CD300lf cooperates with CD300a to inhibit BMMCs activation. CD300lf also colocalized with extracellular ceramide in addition to the internal PS on the cell surface, which results in stronger inhibition of MC activation than CD300lf binding to PS alone. Similarly, although both Cd300a–/– and Cd300lf–/– mice showed decreased rectal temperatures compared with WT mice in the model of passive systemic anaphylaxis, Cd300a–/–Cd300lf–/– mice showed lower rectal temperature than either Cd300a–/– or Cd300lf–/– mice. Our results demonstrate the cooperativity of multiple inhibitory receptors expressed on MCs and their regulatory functions upon binding to respective ligands.

27 July 2024 in Brachytherapy
Verified
Journal Article
Closed access
TKTerufumi Kawamoto
Terufumi Kawamoto
MOMasaki Oshima
Masaki Oshima
NMNaoya Murakami
Naoya Murakami
NONoriyuki Okonogi
Noriyuki Okonogi
YMYoichi Muramoto
Yoichi Muramoto
NSNaoto Shikama
Naoto Shikama

28 June 2024 in Cancers
Verified
Journal Article
Open access
PDF file
YMYoichi Muramoto
Yoichi Muramoto
NMNaoya Murakami
Naoya Murakami
NONoriyuki Okonogi
Noriyuki Okonogi
JTJun Takatsu
Jun Takatsu
KIKotaro Iijima
Kotaro Iijima
NSNaoto Shikama
Naoto Shikama
Purpose: Analyzing dose distributions to regional lymph-node metastases (RLNMs) in locally advanced cervical cancer (LACC) patients undergoing intracavitary and interstitial hybrid brachytherapy (IC/IS). Methods: Dose distributions of eleven LACC patients with 38 RLNMs, and who received 38 IC/IS sessions were analyzed in EQD2, considering RLNM positions and ipsilateral interstitial needles; these RLNMs, excepting the para-aortic region, were classified into four groups. Results: RLNMs had a median of two ipsilateral interstitial needles per session. Significant differences were observed in total RLNM D90, depending on whether the position was cranial or caudal of the uterine base (85.5 vs. 378.9 cGy, p < 0.0001), and whether the RLNM D90 was associated with a number of ipsilateral interstitial needles between 0–1 or 2 or more (68.4 vs. 112.2 cGy, p = 0.006) per session. At each session, Group 1 RLNMs (cranial of the uterine base, 0–1 ipsilateral interstitial needle) had a mean D90 of 21.1 cGy; Group 2 (cranial, 2 or more), 73.8; Group 3 (caudal, 0–1), 94.7; and Group 4 (caudal, 2 or more), 136.1. Conclusion: RLNMs located caudal of the uterine base associated with two or more ipsilateral interstitial needles in IC/IS had a higher dose contribution, which should be considered when calculating the RLNMs’ dose of external beam boost irradiation.

5 December 2025 in BJR|case reports
Verified
Journal Article
Open access
YKYasuo Kosugi
Yasuo Kosugi
NMNaoya Murakami
Naoya Murakami
TKTatsuki Karino
Tatsuki Karino
YMYoichi Muramoto
Yoichi Muramoto
TKTerufumi Kawamoto
Terufumi Kawamoto
NSNaoto Shikama
Naoto Shikama
Radiation therapy is not mentioned in various guidelines for primary treatment of uterine sarcoma. Radiation therapy is considered useful for palliative purposes, but an optimal radiation schedule has not been established. An 85-year-old woman was recommended to undergo surgery for locally advanced uterine sarcoma of unknown histological subtype, but she refused because of her poor physical and social circumstances. She instead received chemotherapy; however, the lesion progressed, and the patient opted for best supportive care. Palliative radiation therapy was indicated for genital bleeding. She thereafter received the QUAD shot regimen, in which 3.7 Gy was administered twice a day for 2 consecutive days and repeated every 4 weeks for a total dose of 44.4 Gy in 3 cycles. The lesion significantly decreased in size, and no new regional or distant metastases were identified. Although only palliative radiation therapy was initially intended, the favourable response with no new lesion development prompted us to offer additional brachytherapy for curative intent, and the patient accepted. She underwent 2 sessions of uterine cervical intracavitary and interstitial brachytherapy using a gel spacer, and local control of the lesion was achieved at 1-year and 3 months follow-up of treatment without major adverse events. In select patients for whom a favourable response is achieved after the QUAD shot, the addition of intracavitary and interstitial brachytherapy with a gel spacer may result in curative treatment. This therapy could be a very promising and attractive option for patients with uterine sarcoma who have complications or special social circumstances.